Candidiasis Market is estimated to surpass US$ 1,307.2 Million,Globally At CAGR of 4.6% by End Of 2028 | Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A

Market Overview

Candidiasis is an infection caused due to the yeast named candida or also categorized as fungus. It is present in the different parts of the human body including belly, mouth, and on the skin. The yeast is dormant in the human body and can lead to candida infection at any stage in a person’s life and is closely limited to immunity level of the person. There are different types of infections caused due to candidiasis such as thrush/ oropharyngeal candidiasis, genital yeast infection/ invasive infection, and cutaneous candidiasis.

Get FREE Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/229

The global candidiasis market size was valued at US$ 873.8 million in 2017, and is expected to exhibit a CAGR of 4.6% over the forecast period (2018–2026).

Market Drivers

Growing incidence of invasive candidiasis is expected to drive growth of the global candidiasis market during the forecast period.

With growing number of invasive candidiasis and vaginal candidiasis cases and preterm birth is posing significant economic burden on patients. According to the Centers for Disease Control and Prevention (CDC), 2017, candidemia, a form of invasive candidiasis, was one of the most common bloodstream infections in the U.S., with an average incidence of around 9 per 100,000 cases between 2013 and 2017.Moreover, according to the same source, 2017, around 84% of the total healthcare cost and 48% of the hospitalizations for Candida infections were due to invasive candidiasis, where the average cost per hospitalization for invasive candidiasis was around US$ 64,723- US$ 153,090.

Furthermore, health complications pertaining candidiasis during and after pregnancy is expected to propel the global candidiasis is expected to propel the global candidiasis market growth over the forecast period. According to the Centers for Disease Control and Prevention (CDC), in 2015, vaginal candidiasis was the second most common type of vaginal infection after bacterial vaginal infection. The CDC estimates that around 1.4 million outpatient visits for vaginal candidiasis occur annually in the U.S.

𝐂𝐡𝐫𝐢𝐬𝐭𝐦𝐚𝐬 𝐒𝐚𝐥𝐞 𝐈𝐬 𝐋𝐢𝐯𝐞!!!!!!!

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐎 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐓𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏

Purchase This Premium Report With Discounted Rate @ https://www.coherentmarketinsights.com/insight/buy-now/229

Moreover, increasing number of preterm births is expected to boost the global candidiasis market growth over the forecast period. According to the Kolling Institute of Medical Research, 2015, vaginal candidiasis can increase the risk of preterm births. Moreover, according to a survey by researchers from the University of Miyazaki in 2017, the incidence of vulvovaginal candidiasis (VC) during pregnancy is around 13–20% globally. Furthermore, according to the Obstetrics and Gynecology Department, Italy, 2018, VC is estimated to be the second most common cause of vaginitis and is found in 40% of women with vaginal discomfort. VC can cause systemic infections in premature neonates, particularly those with low birth weight.

Market Restraint

Increasing adoption of alternative therapies such as over-the-counter treatment, boric acid capsules, and herbal treatments including probiotic supplements, tea tree oil, etc. for treatment of candidiasis is expected to hamper the global candidiasis market growth over the forecast period.

Market Opportunity

Continuous research and development activities for novel treatments can present lucrative growth opportunities

Key companies are focused on research and development activities, in order to develop innovative treatment options. For instance, in June 2019, microbiologists at the Beth Israel Deaconess Medical Center (BIDMC) demonstrated that combination of anti-fungal and anti-bacterial medications can effectively target multidrug resistant Candida auris. Similarly in October 2018, researchers at the American Society for Microbiology identified a compound alexidine dihydrochloride, which has the highest antifungal and anti-biofilm activity against a diverse range of fungal pathogens, thus having a greater potential for use as a pan-antifungal drug.

Competitive Section

Major players operating in the global candidiasis market include, Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.

Key Developments

• Major institutes and universities are focused on R&D activities related to candidiasis. For instance, on September 09, 2019, a team of researchers from Southmead Hospital, Bristol, in collaboration with Triticum Exploitatie B.V., tested the vulnerability of Candida albicans to honey and an MGH formulation (L-Mesitran) by evaluating five isolates from vaginal samples of symptomatic patients suffering from recurrent vulvovaginal candidiasis.

• In August 2019, researchers from Complutense University of Madrid developed fast-dissolving orodispersible films of amphotericin B for or opharyngeal candidiasis.

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/229

Reasons to Purchase this Report

• Current and future of global Candidiasis Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Drug Class
     • Market Snippet, By Type
     • Market Snippet, By Route of Administration
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Adherence and Switch (U.S.)
   • Market Trends
   • Pipeline Analysis
   • Key Developments
   • Regulatory Scenario
   • Reimbursement Scenario
   • Merger and Acquisition Scenario
   • PEST Analysis
   • Epidemiology
4. Global Candidiasis Market, By Drug Class, 2016 – 2026, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2016 and 2026 (%)
     • Y-o-Y Growth Analysis, 2017 – 2026
     • Segment Trends
   • Azoles
     •  Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
   • Echinocandins
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
   • Polyenes
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
   • Flucytosine
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
5. Global Candidiasis Market, By Type, 2016 – 2026, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2016 and 2026 (%)
     • Y-o-Y Growth Analysis, 2017 – 2026
     • Segment Trends
   • Candida infections of the mouth, throat, and esophagus
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
   • Vaginal candidiasis
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
   • Invasive/Systemic candidiasis
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
6. Global Candidiasis Market, By Route of Administration, 2016 – 2026, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2016 and 2026 (%)
     • Y-o-Y Growth Analysis, 2017 – 2026
     • Segment Trends
   • Oral
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
   • Parenteral
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
   • Topical
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
7. Global Candidiasis Market, By Distribution Channel, 2016 – 2026, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2016 and 2026 (%)
     • Y-o-Y Growth Analysis, 2017 – 2026
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
   • Online Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
8. Global Candidiasis Market, By Region, 2016 – 2026, (US$ Mn)
   • Introduction
     • Market Share Analysis, By Region, 2016 and 2026 (%)
     • Y-o-Y Growth Analysis, For Regions, 2017–2026
   • North America
     • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
       • U.S.
       • Canada
   • Latin America
     • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
       • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Europe
     • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
       • Germany
       • U.K.
       • France
       • Italy
       • Spain
       • Russia
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
       • China
       • India
       • Japan
       • Australia
       • South Korea
       • ASEAN
       • Rest of Asia Pacific
   • Middle East
     • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Mn)
       • GCC
       • Israel
       • Rest of Middle East
   • Africa
     • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
     • Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Mn)
       • South Africa
       • Central Africa
       • North Africa

View Press Release: https://www.coherentmarketinsights.com/press-release/candidiasis-market-to-surpass-us-13072-million-by-2026-2454

About Us: